Novel active ingredients that support joint health by their disease-modifying anti-inflammatory & cartilage protecting pathways
Disease-modifying mechanism of action that have been evaluated through multiple pre-clinical studies
Activates T regulatory (Treg) cells which increase the production of anti-inflammatory mediators such as IL-4, IL-10 & TGF-β, which in turn, stimulate chondrocytes to synthesize cartilage matrix components
Inhibits production of cartilage degrading enzymes, matrix metalloproteinases MMP-3 & MMP-13, which prevents cartilage breakdown
Reduce the production of pro-inflammatory mediators such as 5-lipooxygenase, IL-1β, TNF-α, IL-2 & IL-17
Clinical trials have shown efficacy & safety in osteoarthritis patients
